RNA interference for treating haematological malignancies

Bibliography

• COOLS J, DEANGELO DJ, GOTLIB J et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N EngL J. Med. (2003) 348(13):1201–1214.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N EngL J. Med. (2001) 344(14):1031–1037.
   PubMed Web of Science ®Google Scholar
• FAGARD M, BOUTET S, MOREL JB, BELLINI C, VAUCHERET H: AG01, QDE-2, and RDE-1 are related proteins required for post-transcriptional gene silencing in plants, quelling in fungi, and RNA interference in animals. Proc. Nail. Acad. Sci. USA (2000) 97(21):11650–11654.
   PubMed Web of Science ®Google Scholar
• LECELLIER CH, DUNOYER P, ARAR K et al.: A cellular microRNA mediates antiviral defense in human cells. Science (2005) 308(5721):557–560.
   PubMed Web of Science ®Google Scholar
• TABARA H, SARKISSIAN M, KELLY WG et al.: The rde-1 gene, RNA interference, and transposon silencing in C. elegans. Cell (1999) 99(2):123–132.
   PubMed Web of Science ®Google Scholar
• NOVINA CD, SHARP PA: The RNAi revolution. Nature (2004) 430(6996):161–164.
   PubMed Web of Science ®Google Scholar
• LIM LP, LAU NC, WEINSTEIN EG et al.: The microRNAs of Caenorhabditis elegans. Genes Dev. (2003) 17(8):991–1008.
   PubMed Web of Science ®Google Scholar
• GIRALDEZ AJ, CINALLI RM, GLASNER ME et al.: MicroRNAs regulate brain morphogenesis in Zebrafish. Science (2005) 308(5723):833–838.
   PubMed Web of Science ®Google Scholar
• CHEN CZ, LI L, LODISH HF, BARTEL DP: MicroRNAs modulate hematopoietic lineage differentiation. Science (2004) 303(5654):83–86.
   PubMed Web of Science ®Google Scholar
• LAGOS-QUINTANA M, RAUHUT R, YALCIN A, MEYER J, LENDECKEL W, TUSCHL T: Identification of tissue-specific microRNAs from mouse. Curr. Biol. (2002) 12(9):735–739.
   PubMed Web of Science ®Google Scholar
• GAUWERKY CE, HUEBNER K, ISOBE M, NOWELL PC, CROCE CM: Activation of MYC in a masked t(8;17) translocation results in an aggressive B-cell leukemia. Proc. Nail. Acad. Sci. USA (1989) 86(22):8867–8871.
   PubMed Web of Science ®Google Scholar
• LEE Y, AHN C, HAN J et al.: The nuclear RNase III Drosha initiates microRNA processing. Nature (2003) 425(69561:415–419.
   PubMed Web of Science ®Google Scholar
• YANG D, LU H, ERICKSON JW: Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi in Drosophila embryos. Curr. Biol. (2000) 10(19):1191–1200.
   PubMed Web of Science ®Google Scholar
• ELBASHIR SM, MARTINEZ J, PATKANIOWSKA A, LENDECKEL W, TUSCHL T: Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. (2001) 20(23):6877–6888.
   PubMed Web of Science ®Google Scholar
• ZAMORE PD, TUSCHL T, SHARP PA, BARTEL DP: RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell (2000) 101(1):25–33.
   PubMed Web of Science ®Google Scholar
• LIU J, CARMELL MA, RIVAS FV et al.: Argonaute2 is the catalytic engine of mammalian RNAi. Science (2004) 305(5689):1437–1441.
   PubMed Web of Science ®Google Scholar
• SONG JJ, SMITH SK, HANNON GJ, JOSHUA-TOR L: Crystal structure of Argonaute and its implications for RISC slicer activity. Science (2004) 305(5689):1434–1437.
   PubMed Web of Science ®Google Scholar
• RAND TA, GINALSKI K, GRISHIN NV, WANG X: Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc. Nail. Acad. Sci. USA (2004) 101(4014385–14389.
   Web of Science ®Google Scholar
• ALEXOPOULOU L, HOLT AC, MEDZHITOV R, FLAVELL RA: Recognition of double-stranded RNA and activation of NF-lcappaB by Toll-like receptor 3. Nature (2001) 413(6857):732–738.
   PubMed Web of Science ®Google Scholar
• JUDGE AD, SOOD V SHAW JR, FANG D, MCCLINTOCK K, MACLACHLAN I: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. (2005) 23(4):457–462.
   PubMed Web of Science ®Google Scholar
• HORNUNG V GUENTHNER-BILLER M, BOURQUIN C et al.: Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. (2005) 11(3):263–270.
   PubMed Web of Science ®Google Scholar
• SIOLAS D, LERNER C, BURCHARD J et al.: Synthetic shRNAs as potent RNAi triggers. Nat. Biotechnol. (2005) 23(2):227–231.
   PubMed Web of Science ®Google Scholar
• KIM DH, BEHLKE MA, ROSE SD, CHANG MS, CHOI S, ROSSI JJ: Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. (2005) 23(2):222–226.
   PubMed Web of Science ®Google Scholar
• JOHN B, ENRIGHT AJ, ARAVIN A. TUSCHL T, SANDER C, MARKS DS: Human microRNA targets. PLoS Biol. (2004) 2(11):e363.
   Google Scholar
• LIPPMAN Z, MARTIENSSEN R: The role of RNA interference in heterochromatic silencing. Nature (2004) 431(7006):364–370.
   PubMed Web of Science ®Google Scholar
• OPALINSKA JB, GEWIRTZ AM: Therapeutic potential of antisense nucleic acid molecules. Sci. STKE (2003) 2003(206):pe47.
   PubMedGoogle Scholar
• OPALINSKA JB, GEWIRTZ AM: Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. (2002) 1(7):503–514.
   PubMed Web of Science ®Google Scholar
• DAMM-WELK C, FUCHS U, WOSSMANN W, BORKHARDT A: Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference. Semin. Cancer Biol. (2003) 13(4):283–292.
   PubMed Web of Science ®Google Scholar
• WENG AP, FERRANDO AA, LEE W et al.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 306(5694):269–271.
   PubMed Web of Science ®Google Scholar
• PUROW BW, HAQUE RM, NOEL MW et al.: Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. (2005) 65(6):2353–2363.
   PubMed Web of Science ®Google Scholar
• CHI KN, GLEAVE ME, KLASA R et ell.: A Phase I dose-finding study of combined treatment with an antisense Bc1-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res. (2001) 7(12):3920–3927.
   Google Scholar
• JANSEN B, WACHECK V, HEERE-RESS E et al.: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet (2000) 356(9243):1728–1733.
   PubMed Web of Science ®Google Scholar
• WATERS JS, WEBB A, CUNNINGHAM D et al.: Phase I clinical and pharmacokinetic study of bc1-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. Clin. Oncol (2000) 18(9):1812–1823.
   Web of Science ®Google Scholar
• WEBB A. CUNNINGHAM D, COTTER F et al.: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet (1997) 349(9059):1137–1141.
   Google Scholar
• GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293(5531):876–880.
   PubMed Web of Science ®Google Scholar
• REYNOLDS A LEAKE D, BOESE Q, SCARINGE S, MARSHALL WS, KHVOROVA A: Rational siRNA design for RNA interference. Nat. Biotechnol (2004) 22(3):326–330.
   PubMed Web of Science ®Google Scholar
• KHVOROVA A, REYNOLDS A JAYASENA SD: Functional siRNAs and miRNAs exhibit strand bias. Cell (2003) 115(2):209–216.
   PubMed Web of Science ®Google Scholar
• SCHWARZ DS, HUTVAGNER G, DU T, XU Z, ARONIN N, ZAMORE PD: Asymmetry in the assembly of the RNAi enzyme complex. Cell (2003) 115(2):199–208.
   PubMed Web of Science ®Google Scholar
• TOMARI Y, MATRANGA C, HALEY B, MARTINEZ N, ZAMORE PD: A protein sensor for siRNA asymmetry. Science (2004) 306(57001377–1380.
   Web of Science ®Google Scholar
• CHIU YL, RANA TM: siRNA function in RNAi: a chemical modification analysis. RNA (2003) 9(9):1034–1048.
   PubMed Web of Science ®Google Scholar
• CHIEN PY, WANG J, CARBONARO D et al.: Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther. (2005) 12(3):321–328.
   PubMed Web of Science ®Google Scholar
• LANDEN CN JR, CHAVEZ-REYES k BUCANA C et al.: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. (2005) 65(15):6910–6918.
   Google Scholar
• ZHANG Y, ZHANG YF, BRYANT J, CHARLES A, BOADO RJ, PARDRIDGE WM: Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. (2004) 10(11):3667–3677.
   PubMed Web of Science ®Google Scholar
• SOUTSCHEK J, AKINC A, BRAMLAGE Bet al.: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 432(7014):173–178.
   Google Scholar
• HACHEM A. GARTENHAUS RB: Oncogenes as molecular targets in lymphoma. Blood (2005) 106(6):1911–1923.
   PubMed Web of Science ®Google Scholar
• SONNICHSEN B, KOSKI LB, WALSH A et al.: Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans. Nature (2005) 434(7032):462–469.
   PubMed Web of Science ®Google Scholar
• ZHENG L, LIU J, BATALOV S et al: An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc. Nail. Acad. Sci. USA (2004) 101(1):135–140.
   PubMed Web of Science ®Google Scholar
• BERNS K, HUMANS EM, MULLENDERS Jet al: A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 428(6980:431–437.
   PubMed Web of Science ®Google Scholar
• LADETTO M, CORRADINI P, VALLET S et al: High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood (2002) 100(5):1559–1565.
   PubMed Web of Science ®Google Scholar
• JACOBSEN E, FREEDMAN A: B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. Lancet Oncol (2004) 5(12):711–717.
   PubMed Web of Science ®Google Scholar
• HECKMAN CA, WHEELER MA, BOXER LM: Regulation of Bc1-2 expression by C/EBP in 04;18) lymphoma cells. Oncogene (2003) 22(39):7891–7899.
   PubMed Web of Science ®Google Scholar
• PTASZNIK A, NAKATA Y, KALOTA A, EMERSON SG, GEWIRTZ AM: Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat. Med. (2004) 10(11):1187–1189.
   PubMed Web of Science ®Google Scholar
• WEISBERG E, BOULTON C, KELLY LM et al: Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell (2002) 1(5):433–443.
   PubMed Web of Science ®Google Scholar
• CLARK JJ, COOLS J, CURLEY DP et al: Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood (2004) 104(9):2867–2872.
   PubMed Web of Science ®Google Scholar
• WALTERS DK, STOFFREGEN EP, HEINRICH MC, DEININGER MW DRUKER BJ: RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood (2005) 105(7):2952–2954.
   PubMed Web of Science ®Google Scholar
• WOHLBOLD L, VAN DER KUIP H, MIETHING C et al: Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood (2003) 102(6):2236–2239.
   PubMed Web of Science ®Google Scholar
• GODFREY A, ANDERSON J, PAPANASTASIOU A, TAKEUCHI Y, BOSHOFF C: Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood (2005) 105(6):2510–2518.
   PubMed Web of Science ®Google Scholar
• SHEN J, SAMUL R, SILVA RL et ell.: Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. (2005) (In Press).
   Google Scholar
• ROBBINS MA, ROSSI JJ: Sensing the danger in RNA. Nat. Med. (2005) 11(3):250–251.
   PubMed Web of Science ®Google Scholar
• SHANKAR P, MANJUNATH N, LIEBERMAN J: The prospect of silencing disease using RNA interference. JAMA (2005) 293(11):1367–1373.
   PubMed Web of Science ®Google Scholar
• STEVENSON M: Therapeutic potential of RNA interference. N Engl. J. Med. (2004) 351(17):1772–1777.
   PubMed Web of Science ®Google Scholar
• http://www.rockefelletedu/labheads/tuschl/ sirna.html Tuschl lab - The siRNA user guide.
   Google Scholar
• http://jura.wi.mit.edu/siRNAext/ siRNA at Whitehead. Bioinformatics and research computing.
   Google Scholar